Inhibition of host Ogr1 enhances effector CD8+ T-cell function by modulating acidic microenvironment
© 2021. The Author(s)..
Immunotherapies for cancer, such as immune checkpoint blockade or adoptive T-cell transfer, can lead to a long-lasting clinical response. But the therapeutic response rate remains low on account of many tumors that have evolved sophisticated strategies to evade immune surveillance. Solid tumors are characterized by the highly acidic microenvironment, which may weaken the effectiveness of antitumor immunity. Here, we explored a promising therapeutic development deployed by pH manipulation for avoiding immunoevasion. The highly acidified microenvironment of melanoma induces the expression of G-protein-coupled receptor (Ogr1) in T cells, which weakened their effective function and promote tumor growth. Ogr1 inhibition reactivate CD8+ T cells and have a cytotoxic role by reducing the activity of high glycolysis, resulting in comparatively low acidification of the tumor microenvironment, and leads to tumor suppression. In addition, the adoptive transfer of Ogr1-/--CD8+ T cells enhanced the antitumor responses, with the potential for immediate clinical transformation.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Cancer gene therapy - 28(2021), 10-11 vom: 22. Nov., Seite 1213-1224 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cao, Lin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
GPR68 protein, mouse |
|---|
| Anmerkungen: |
Date Completed 01.03.2022 Date Revised 27.10.2022 published: Print-Electronic ErratumIn: Cancer Gene Ther. 2021 Oct 4;:. - PMID 34608269 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41417-021-00354-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327059613 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327059613 | ||
| 003 | DE-627 | ||
| 005 | 20231225195934.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41417-021-00354-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM327059613 | ||
| 035 | |a (NLM)34158625 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cao, Lin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inhibition of host Ogr1 enhances effector CD8+ T-cell function by modulating acidic microenvironment |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.03.2022 | ||
| 500 | |a Date Revised 27.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Cancer Gene Ther. 2021 Oct 4;:. - PMID 34608269 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a Immunotherapies for cancer, such as immune checkpoint blockade or adoptive T-cell transfer, can lead to a long-lasting clinical response. But the therapeutic response rate remains low on account of many tumors that have evolved sophisticated strategies to evade immune surveillance. Solid tumors are characterized by the highly acidic microenvironment, which may weaken the effectiveness of antitumor immunity. Here, we explored a promising therapeutic development deployed by pH manipulation for avoiding immunoevasion. The highly acidified microenvironment of melanoma induces the expression of G-protein-coupled receptor (Ogr1) in T cells, which weakened their effective function and promote tumor growth. Ogr1 inhibition reactivate CD8+ T cells and have a cytotoxic role by reducing the activity of high glycolysis, resulting in comparatively low acidification of the tumor microenvironment, and leads to tumor suppression. In addition, the adoptive transfer of Ogr1-/--CD8+ T cells enhanced the antitumor responses, with the potential for immediate clinical transformation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a GPR68 protein, mouse |2 NLM | |
| 650 | 7 | |a Receptors, G-Protein-Coupled |2 NLM | |
| 700 | 1 | |a Li, Weisha |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xingjiu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wenlong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Mengyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Haizeng |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Chuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiaohong |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Ran |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer gene therapy |d 1997 |g 28(2021), 10-11 vom: 22. Nov., Seite 1213-1224 |w (DE-627)NLM075187256 |x 1476-5500 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2021 |g number:10-11 |g day:22 |g month:11 |g pages:1213-1224 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41417-021-00354-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2021 |e 10-11 |b 22 |c 11 |h 1213-1224 | ||